Name of journal: *World Journal of Clinical Cases*

ESPS Manuscript NO: 11027

Columns: CASE REPORT

**Pneumatosis cystoides intestinalis associated with toxic epidermal necrolysis: A case report**

Yao SY *et al.* PCI associated with TEN

Si-Yuan Yao, Ryutaro Seo, Tohru Nagano, Kazuo Yamazaki

**Si-Yuan Yao,** Departments of Surgery, Kobe City Medical Center General Hospital, Chuo-ku, Kobe 650-0047, Japan

**Ryutaro Seo, Kazuo Yamazaki,** Departments of Anesthesiology, Kobe City Medical Center General Hospital, Chuo-ku, Kobe 650-0047, Japan

**Tohru Nagano,** Departments of Dermatology, Kobe City Medical Center General Hospital, Chuo-ku, Kobe 650-0047, Japan

**Author contributions:** Yao SY, Seo R, Nagano T and Yamazaki K contributed to the manuscript writing and revision.

**Correspondence to: Si-Yuan Yao, MD,** Departments of Surgery, Kobe City Medical Center General Hospital, 2-1-1, Minatojima-Minamimachi, Chuo-ku, Kobe, 650-0047, Japan. siyuan@kobe-nishishimin-hospi.jp

**Telephone:** +81-78-3024321　**Fax:** +81-78-3027537

**Received:** April 30, 2014 **Revised:** June 3, 2014

**Accepted:** June 27, 2014

**Published online:**

**Abstract**

Toxic epidermal necrolysis (TEN) is a severe adverse drug reaction, which is characterized by erythema, blisters, and/or erosions of the mucous membranes and skin, but intestinal involvement is rare. In contrast, pneumatosis cystoides intestinalis (PCI) is a rare condition associated with a wide variety of underlying diseases, but to date no patient has presented with PCI associated with TEN. A 55-year-old man was admitted to intensive care unit for treatment of TEN caused by phenobarbital. On day 8 after admission, he presented with progressive abdominal distention and hypotension. Computed tomography (CT) showed gas in the superior mesenteric vein and air filled cysts in the walls of the small intestine. He was suspected of having septic shock due to PCI. As there were no indications of bowel ischemia or necrosis, the patient was managed conservatively with antibiotics and oxygen therapy. On day 10 after admission, he was weaned off catecholamines, with CT on day 11 showing complete resolution of gas in the superior mesenteric vein and air filled cysts. To our knowledge, this article describes the first patient presenting with PCI associated with TEN.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words:** Toxic epidermal necrolysis; Intestinal involvement; Pneumatosis cystoids intestinalis; Septic shock; Conservative treatment

**Core tip:** Toxic epidermal necrolysis is a severe adverse drug reaction, which affects skin and mucosa of whole body. However, intestinal involvement is rare documented. We report the case of a 55-year-old man with toxic epidermal necrolysis caused by phenobarbital. He was diagnosed with pneumatosis cystoides intestinalis during the clinical course. Although septic shock was accompanied, conservative treatment was effective. To our knowledge, this article describes the first patient presenting with pneumatosis cystoides intestinalis associated with toxic epidermal necrolysis.

Yao SY, Seo R, Nagano T, Yamazaki K. Pneumatosis cystoides intestinalis associated with toxic epidermal necrolysis: A case report. *World J Clin Cases* 2014; In press

**INTRODUCTION**

Toxic epidermal necrolysis (TEN) is a rare but potentially fatal condition often caused by adverse drug reactions. TEN is characterized by high fever, widespread blistering of the exanthematous macules and atypical target-like lesions of the skin, as well as mucosal involvement. However, there have been few reports of intestinal involvement of TEN[1].

Pneumatosis cystoides intestinalis (PCI) is a rare condition, in which submucosal or subserosal gas cysts are found in the walls of the small and/or large intestines. The pathogenesis of PCI remains unclear, and the role of emergency surgical intervention in patients with PCI accompanied by portal vein gas or peritoneal irritation remains controversial.

We describe here a patient with PCI encountered during the clinical course of TEN, with the former condition successfully treated by conservative management. To our knowledge, this is the first such patient described to date.

**CASE REPORT**

A 55-year-old man with a previous medical history of alcohol-induced epilepsy presented to our dermatology department with complaints of fever and a rapidly evolving rash over his face and trunk. He had been taking two antiepileptic agents, carbamazepine and phenobarbital, for one month. Drug induction was suspected, and oral antihistamine and steroids were started after discontinuation of the antiepileptics.

Despite this treatment, the rash did not improve, spreading to his back, arms, and legs after one week. He was admitted to our hospital with a presumed diagnosis of Stevens–Johnson syndrome (SJS). On the day of admission, he was started on intravenous steroid pulse therapy with prednisolone plus immunoglobulin. However, blister and erosion continued to spread throughout the entire body (Figure 1). The patient was diagnosed with TEN and transferred to intensive care unit (ICU) on day 6 of hospitalization. During his stay in the ICU, his skin condition gradually improved with continuous intravenous steroids. He was also administered a first generation cefem for antibiotic prophylaxis.

Abdominal distension was also observed, beginning on the third day of admission. CT scan performed on day 5 showed no specific findings except for pneumocolon. The patient was put on a bowel regimen, consisting of laxatives and enemas, to regulate his bowel movements.

On day 8, the condition of this patient suddenly deteriorated. His abdominal distension became exacerbated and his blood pressure decreased rapidly. He became less responsive and scored 11 (E2V4M5) on the Glasgow Coma Scale.

Physical examination showed a temperature of 37.2°C, blood pressure of 60/28 mmHg, pulse of 110 beats per minute, and oxygen saturation 97% in ambient air. Abdominal examination showed marked fullness and diffuse rebound tenderness throughout the entire abdomen. Laboratory examinations revealed severe acidosis and elevated lactic acid concentration. The results of laboratory examinations are shown in Table 1. A blood culture was positive for a species of Corynebacterium.

Plain abdominal radiography showed small-bowel distension and a low-density linear and bubbly pattern of gas in the small-bowel wall (Figure 2). A non-contrast CT scan revealed gas in the superior mesenteric vein (SMV) and intramural air, but no free air, in the small-bowel wall (Figure 3). The patient was preliminarily diagnosed with septic shock associated with pneumatosis cystoides intestinalis. He was started immediately on oxygen treatment, followed by intravenous broad-spectrum antibiotics and catecholamine. Although an emergency laparotomy was considered, the patient’s general condition was too poor to tolerate an operation, and there was no sign of bowel ischemia or necrosis. Therefore, the patient was managed conservatively.

The patient progressed well, recovering from a catecholamine-dependent state two days later. A CT scan, performed three days later, showed that the gas in the small bowel wall had completely disappeared. The abdominal fullness gradually remitted and he was discharged from the ICU after sixteen days. Several days later, a drug lymphocyte stimulating test (DLST) was positive for phenobarbital, indicating that phenobarbital had caused TEN in this patient.

The patient’s skin condition completely resolved sixty-two days after admission. No recurrence of PCI and TEN have been observed for three years.

**DISCUSSION**

Stevens–Johnson syndrome and TEN are rare diseases, affecting approximately 1 or 2 per million individuals annually. Both of these diseases are considered medical emergencies as they are potentially fatal[2].

Currently, TEN and SJS are considered to be at the two ends of a spectrum of severe epidermolytic adverse cutaneous drug reactions, differing only in their extent of skin detachment. Symptoms of SJS include acute conditions characterized by mucous membrane erosions and skin lesions (described as macules, atypical target-like lesions, bulla, and erosions) involving less than 10% of the total skin surface area, whereas TEN involves more than 10% of the total skin surface area. In addition to skin symptoms, both diseases are often accompanied by complications in numerous organs, including the liver, kidneys, and lungs. The mortality rate for patients with TEN has been reported to range from 25% to 35%[2,3].

Certain drugs, including sulfonamides, non-steroidal anti-inflammatory drugs, cephem antibiotics, barbiturates, and antiepileptics are the most frequent triggers of TEN. A DLST for phenobarbital was positive in this patient, and the TEN was retrospectively determined to be a drug eruption caused by phenobarbital, with the condition progressing to TEN from SJS during its clinical course.

Pneumatosis cystoides intestinalis (PCI) is an unusual intestinal condition characterized by the presence of gas within the intestinal wall, usually in the mucosa and submucosa of the small and large intestines. PCI has been classified as primary or secondary, with most patients having secondary PCI due to an underlying condition[4]. These underlying conditions have been classified as (1) traumatic and mechanical (*e.g.*, pyloric stenosis, endoscopy, enteric tube placement volvulus, surgical anastomosis, carcinoma); (2) inflammatory and auto- immune (*e.g*., Crohn’s disease, ulcerative colitis, diverticular disease, necrotizing enterocolitis, polydermatomyositis, scleroderma, mixed connective tissue disease, multiple sclerosis); (3) infectious (*e.g.*, Clostridium difficile, HIV/AIDS, cytomegalovirus, Mycobacterium species); (4) pulmonary (*e.g.*, chronic obstructive pulmonary disease, asthma, cystic fibrosis); (5) drug induced (*e.g.*, cytotoxic agents, immunosuppressants, corticosteroids); or (6) other conditions, such as transplantation, graft versus host disease, leukemia, or intestinal infarction[5].

The pathogenesis of PCI is unclear, although several hypotheses have been suggested. The gas within the intestine wall may be intraluminal, pulmonary or produced by bacteria[5,6]. Mechanical features thought to be responsible for intrusion of intraluminal gas into the bowel wall are mucosal injury and/or increased intraluminal pressure. The possibility of pulmonary gas as a source for PCI is based on the hypothesis that air migrates along vessels within the mediastinum, retroperitoneum and mesentery after alveolar rupture in pulmonary diseases.

PCI may be asymptomatic or may manifest symptoms and signs associated with life threatening complications, such as bowel ischemia, perforation and peritonitis. Generally, however, the symptoms of PCI are mild and include abdominal pain, diarrhea or constipation, abdominal distension, bloody stools and/or weight loss. About 3% of patients experience more serious symptoms, including bleeding, ileus, volvulus, intussusception, and/or pneumoperitoneum[7].

Treatment for PCI depends on its symptoms, with no specific treatment standardized. PCI may be detected incidentally by radiographic imaging, screening colonoscopy, or during laparotomy. Intramural gas cysts in asymptomatic patients usually resolve spontaneously over time. Patients with mild to moderate symptoms are usually treated conservatively, with antibiotics, oxygen, and hyperbaric oxygen therapy reported effective[8,9]. Emergency surgical exploration is indicated for patients with suspected intestinal necrosis or abdominal sepsis[10]. Immediate surgery has been indicated for patients with elevated C-reactive protein or WBC, or the signs of sepsis, bowel perforation or portal venous gas. Conservative therapy has been recommended for patients with normal or slightly increased inflammatory parameters in blood samples and no signs of sepsis, bowel perforation or free gas[11].

Since the first report of PCI in France in the 18th century, numerous case reports and reviews have appeared worldwide. However, intestinal lesions in patients with TEN have rarely been reported. To our knowledge, our patient is the first reported to have TEN associated with PCI. Four patients with TEN were reported to present with digestive symptoms, including abdominal pain and bloody diarrhea. Pathological examination of mucosal biopsy specimens revealed that the superficial epithelium was severely damaged by necrosis, while the lamina propia was relatively unaffected[1] {Chosidow, 1991 #33}.

PCI has been reported associated with collagen skin diseases, including scleroderma and dermatomyositis[10,12]. These patients are often treated with corticosteroids, which can induce atrophy of the mucosa and mucosal defects facilitating the intrusion of gas and bacteria[13].

Our patient was treated intravenously with high dose corticosteroids for 15 d, which may have exacerbated the atrophy and necrosis of the intestinal mucosa, which had been damaged by TEN. Persistent constipation may result in chronically elevated intra-luminal pressure, inducing the invasion of intramural compartments by gas and bacteria. The fragility of his intestinal mucosa allowed bacterial translocation and resulted in septic shock of Corynebacterium.

The signs of peritoneal irritation and gas in the SMV suggested the need for an emergency laparotomy, but his poor general condition did not allow surgery. In addition, we were unable to identify any underlying disease that could have induced ischemia or necrosis of the intestine. Conservative treatment with antibiotics, catecholamine, and oxygen therapy was successful. His abdominal symptoms disappeared and he discharged from the ICU after 8 d. In general, patients with signs of peritonitis in addition to metabolic acidosis indicating septic shock are candidates for surgery. However, in the absence of life-threatening situations such as perforation or necrosis, PCI can be managed conservatively. PCI is a clinical sign, and is not itself a diagnosis. Careful evaluation of the underlying disease and accompanying symptoms is essential.

**ACKNOWLEDGEMENTS**

The authors thank edanz.Ltd who provided medical writing services.

**COMMENTS**

***Case characteristics***

A 55-year-old male patient under the treatment of toxic epidermal necrolysis presented abdominal distension and fell into state of shock.

***Clinical diagnosis***

The patient was diagnosed with pneumatosis cystoides intestinalis.

***Differential diagnosis***

Perforative peritonitis, acute mesenteric artery occlusion.

***Laboratory diagnosis***

The patient had severe acidosis (a blood pH of 7.121), acute renal damage (blood urea nitrogen 85 mg/dL, creatine 2.61 mg/dL) and elevated C-reactive protein (10.3 mg/dL).

***Imaging diagnosis***

A non-contrast computed tomography scan revealed gas in the superior mesenteric vein and intramural air in the small-bowel wall.

***Pathological diagnosis***

No pathological specimen was obtained but a blood culture was positive for a species of Corynebacterium, showing that the patient had been in the state of sepsis due to pneumatosis cystoides intestinalis.

***Treatment***

Conservative management including oxygen treatment, intravenous broad-spectrum antibiotics and catecholamine was successful.

***Related reports***

Toxic epidermal necrolysis is a severe adverse drug reaction, which is characterized by erythema, blisters, and/or erosions of the mucous membranes and skin in whole body, but intestinal involvement is rare reported.

***Experiences and lessons***

Pneumatosis cystoides intestinalis can be observed during the treatment course of toxic epidermal necrolysis and conservative management is possibly effective when there are no signs of ischemia or necrosis of the intestine.

***Peer review***

This is an interesting case report of pneumatosis cystoides intestinalis associated with toxic epidermal necrolysis. The manuscript is clearly written, and this unusual presentation has clinical relevance.

**REFERENCES**

1 **Chosidow O**, Delchier JC, Chaumette MT, Wechsler J, Wolkenstein P, Bourgault I, Roujeau JC, Revuz J. Intestinal involvement in drug-induced toxic epidermal necrolysis. *Lancet* 1991; **337**: 928 [PMID: 1673016 DOI: 10.1016/0140-6736(91)90273-R]

2 **Harr T**, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. *Orphanet J Rare Dis* 2010; **5**: 39 [PMID: 21162721 DOI: 10.1186/1750-1172-5-39]

3 **Yamane Y**, Aihara M, Ikezawa Z. Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in Japan from 2000 to 2006. *Allergol Int* 2007; **56**: 419-425 [PMID: 17713361 DOI: 10.2332/allergolint.O-07-483]

4 **KOSS LG**. Abdominal gas cysts (pneumatosis cystoides intestinorum hominis); an analysis with a report of a case and a critical review of the literature. *AMA Arch Pathol* 1952; **53**: 523-549 [PMID: 14923068]

5 **St Peter SD**, Abbas MA, Kelly KA. The spectrum of pneumatosis intestinalis. *Arch Surg* 2003; **138**: 68-75 [PMID: 12511155 DOI: 10.1001/archsurg.138.1.68]

6 **Pear BL**. Pneumatosis intestinalis: a review. *Radiology* 1998; **207**: 13-19 [PMID: 9530294]

7 **Galandiuk S**, Fazio VW. Pneumatosis cystoides intestinalis. A review of the literature. *Dis Colon Rectum* 1986; **29**: 358-363 [PMID: 3516602 DOI: 10.1007/BF02554132]

8 **Tak PP**, Van Duinen CM, Bun P, Eulderink F, Kreuning J, Gooszen HG, Lamers CB. Pneumatosis cystoides intestinalis in intestinal pseudoobstruction. Resolution after therapy with metronidazole. *Dig Dis Sci* 1992; **37**: 949-954 [PMID: 1587203 DOI: 10.1007/BF01300397]

9 **Togawa S**, Yamami N, Nakayama H, Shibayama M, Mano Y. Evaluation of HBO2 therapy in pneumatosis cystoides intestinalis. *Undersea Hyperb Med* 2004; **31**: 387-393 [PMID: 15686270]

10 **Braumann C**, Menenakos C, Jacobi CA. Pneumatosis intestinalis--a pitfall for surgeons? *Scand J Surg* 2005; **94**: 47-50 [PMID: 15865117]

11 **Schröpfer E**, Meyer T. Surgical aspects of pneumatosis cystoides intestinalis: two case reports. *Cases J* 2009; **2**: 6452 [PMID: 19918585 DOI: 10.4076/1757-1626-2-6452]

12 **Balbir-Gurman A**, Brook OR, Chermesh I, Braun-Moscovici Y. Pneumatosis cystoides intestinalis in scleroderma-related conditions. *Intern Med J* 2012; **42**: 323-329 [PMID: 22432985 DOI: 10.1111/j.1445-5994.2011.02557.x]

13 **Höer J**, Truong S, Virnich N, Füzesi L, Schumpelick V. Pneumatosis cystoides intestinalis: confirmation of diagnosis by endoscopic puncture a review of pathogenesis, associated disease and therapy and a new theory of cyst formation. *Endoscopy* 1998; **30**: 793-799 [PMID: 9932761 DOI: 10.1055/s-2007-1001424]

**P-Reviewers:** Bourgoin SG, Chen GS **S-Editor:** Ji FF **L-Editor: E-Editor:**



**Figure 1 Skin findings in this patient.** A and B: Wide-spread blistering exanthemas of macules around the face and neck; C: Nikolsky phenomenon (slight rubbing of the skin resulting in exfoliation of the outermost layer) of the lower leg.



**Figure 2 Plain supine abdominal radiography of patient on day 8 of admission to the intensive care unit, showing small-bowel distension and pneumatosis cystoides intestinalis (arrows).**



**Figure 3 Abdominal computed tomography of patient on day 8 of admission to the intensive care unit, showing.** A: Gas in the superior mesenteric vein (arrow); B: Extraluminal gas along the small bowel mesentery (arrows).

**Table 1 Laboratory data on day 8**

|  |  |  |
| --- | --- | --- |
| Laboratory investigation | Results  | Reference ranges |
| **Arterial blood gas** |  |  |
| Blood pH  | 7.121 | 7.42 ± 0.04 |
| PaCO2 (mmHg) | 24.5 | 32-46 |
| PaO2 (mmHg) | 83.6 | 74-100  |
| Base excess (mmol/L) | -7.3 |  -2-2  |
| Lactic acid (mmol/L) | 2.6 |  0.44-1.78  |
| Plasma bicarbonate (mmol/L) | 15.6 | 21-29  |
| **Serum chemistry** |  |  |
| Serum albumin (g/dL) | 1.6 | 3.8-5.1 |
| Asparate aminotransferase (IU/mL) | 28 | 9-35  |
| Alanine aminotransferase (IU/mL) | 14 | 5-36  |
| Blood urea nitrogen (mg/dL) | 85 | 6-22 |
| Creatine (mg/dL) | 2.61 | 0.47-0.79  |
| C-reactive protein (mg/dL) | 10.3 | 0-0.5 |
| Blood glucose (mg/dL) | 104 | 70-109 |
| **Blood count** |  |  |
| WBC (/μL) | 7.4 × 103 | 3.9-9.8 |
| Hemoglobin (g/dL) | 9.5 | 13.4-17.6 |
| Hematocrit (%) | 30.4 | 39-52 |
| Platelet count (/μL) | 7.9 × 104 | 13-37 |
| Prothrombin time-INR | 1.17 | 0.9-1.1 |